Ohana Vaccines, LLC
Vaccine Immunotherapy for Prostate Cancer Without Significant Side Effects
Ohana Vaccines uses a proprietary prime-boost strategy to cause the destruction of established prostate cancer
IMMUNOTHERAPY
IS THE NEW SOLUTION
OPPORTUNITY
With an estimated $19B total prostate cancer treatment cost by 2020, Ohana Vaccine targets the 20-30% of recurrent prostate cancer.
RAPID GROWTH
Ohana Vaccines is on track to complete clinical trials by the end of 2018 and is ready to scale rapidly to production.
QUICK RETURN
A patent is already filed and there are no comparable competitive Immunotherapy treatments.
Prostate Cancer Treatment Opportunities
1,100,000
161,360
~ 30 %
Globally there are 1.11 M new cases and 307,000 deaths.
In 2018, 164,650 men in the US will be diagnosed with prostate cancer and greater than 26,000 will die.
After initial treatment, about
20-30% of men will show signs of cancer recurrence.
THE PROBLEM
PROSTATE
CANCER RECURRENCE
Following initial treatments for prostate cancer, 20% to 30% of patients will have a recurrence of the disease.
DEATH FROM CANCER IS INEVITABLE
Additional treatments can extend survival but there is no cure for recurrent prostate cancer. Metastatic spread of the cancer is inevitable.
STRONG
SIDE
EFFECTS
All current treatments are accompanied by significant side effects reducing the patient’s quality of life.
THE SOLUTION
Immunotherapy is the new solution – they only destroy antigen-expressing tumor cells and have no effect on normal cells
Business Insider
Aug 3, 2017
Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy
Genetic Engineering & Biotechnology News
Aug 8, 2017
